%0 Journal Article %A Junko Kurita %A Tamie Sugawara %A Yasushi Ohkusa %T Estimating Vaccination Effects on COVID-19 outbreak course in Japan %D 2021 %R 10.1101/2021.06.20.21259209 %J medRxiv %P 2021.06.20.21259209 %X Background Japan started vaccinations for COVID-19 in late February, 2021, mainly using BNT162b2 mRNA COVID-19 Vaccine.Object We evaluated COVID-19 vaccination effects on infectiousness in Japan. Method: The effective reproduction number R(t) was regressed on vaccine coverage along with data of temperature, humidity, mobility, and countermeasures. We presumed two definitions for vaccine coverage: at least a single dose with a 12-day delay and a second dose. The study period was February, 2020 through May 16, 2021.Results Estimation results indicate that vaccine coverage significantly and drastically reduced R(t) for both definitions. Results imply that increased first shot coverage by 1% point decreased R(t) by 0.5 with a 12 day delay. Moreover, increased second shot coverage by 1% point, decreased R(t) by 1 immediately.Discussion and Conclusion Vaccination effects might be stronger because the periods when vaccination was started and rapid spread coincide with a decreasing phase of R(t).Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors received no specific funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All information used for this study has been published. There is therefore no ethical issue related to this study. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesJapan Ministry of Health, Labour and Welfare. Press Releases.(in Japanese) https://www.mhlw.go.jp/stf/newpage_10723.html %U https://www.medrxiv.org/content/medrxiv/early/2021/06/22/2021.06.20.21259209.full.pdf